Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | THPO | P40225 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | RGS12 | O14924 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxilofrine SCHEMBL14465574 | 1.00 | ADRA1A (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL14153976 | 1.00 | ADRA1A (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL4256893 | 1.00 | ADRA1A (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL5173040 | 1.00 | ADRA1A (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL5174274 | 0.98 | KMT2A (0.68) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL29354826 | 0.98 | KMT2A (0.68) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| SCHEMBL23999268 | 0.83 | CYP2D6 (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| SCHEMBL20690347 | 0.83 | HIF1A (0.56) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| SCHEMBL23999280 | 0.83 | CYP2D6 (0.67) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR | |
| Oxilofrine SCHEMBL15347269 | 0.82 | TAAR1 (0.65) | ADRA1ACYP2D6CYP2C19CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-12533327-B2 | Hexylamine salts and methods of using hexylamine | THERMOLIFE INTERNATIONAL, LLC (US) | 2026-01-27 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250059612-A1 | METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS | BECTON, DICKINSON AND COMPANY | 2025-02-20 | — | — | US | claimed |
| EP-4473127-A1 | METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS | Becton, Dickinson and Company (US) | 2024-12-11 | — | — | EP | claimed |
| CN-118647731-A | Method for isolating genomic DNA to amplify short nucleic acid targets | 贝克顿迪金森公司 | 2024-09-13 | — | — | CN | claimed |
| EP-4308724-A1 | ISOTHERMAL AMPLIFICATION OF PATHOGENS | Becton, Dickinson and Company (US) | 2024-01-24 | — | — | EP | claimed |
| US-20240016764-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | THERMOLIFE INTERNATIONAL, LLC | 2024-01-18 | — | — | US | claimed |
| CN-117321221-A | Isothermal amplification of pathogens | 贝克顿迪金森公司 | 2023-12-29 | — | — | CN | claimed |
| WO-2023150708-A1 | METHOD FOR SEPARATING GENOMIC DNA FOR AMPLIFICATION OF SHORT NUCLEIC ACID TARGETS | BECTON, DICKINSON AND COMPANY (US) | 2023-08-10 | — | — | WO | claimed |
| EP-1457494-A1 | PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-09-15 | — | — | EP | claimed |
| CN-1463703-A | Nasal cavity preparation for treating long-term allergic reaction coryza | SHANGHAI FAMILY PLANNING SCIEN (CN) | 2003-12-31 | — | — | CN | claimed |
| EP-0995441-B1 | Combination of compounds for treating erectile dysfunctions | PD DR DUNZENDORFER (DE) | 2002-07-24 | — | — | EP | claimed |
| US-5466466-A | Therapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates II | LTS LOHMANN THERAPIE-SYSTEME GMBH & CO. KG (DE) | 1995-11-14 | — | — | US | claimed |
| EP-0384266-B1 | Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents | LOHMANN THERAPIE SYST LTS (DE) | 1994-07-20 | — | — | EP | claimed |
| EP-0311383-B1 | MONOCLONAL ANTIBODY TO METHAMPHETAMINE, PREPARATION OF THE SAME, ASSAY METHOD AND ASSAY KIT OF METHAMPHETAMINE | UBE INDUSTRIES, LTD. (JP) | 1993-10-06 | — | — | EP | claimed |
| US-5215751-A | THERAPEUTIC SYSTEM FOR THE RETARDED AND CONTROLLED TRANSDERMAL OR TRANSMUCOUS ADMINISTRATION OF ACTIVE SUBSTANCES (I) | LTS LOHMANN THERAPIE SYSTEME GMBH & CO. (DE) | 1993-06-01 | — | — | US | claimed |
| EP-0384267-B1 | THERAPEUTIC SYSTEM FOR THE SUSTAINED AND CONTROLLED TRANSDERMAL OR TRANSMUCOSAL DELIVERY OF ACTIVE AGENTS | LTS Lohmann Therapie-Systeme GmbH & Co. KG (DE) | 1993-05-26 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533327-B2 | Hexylamine salts and methods of using hexylamine | SLC6A2, SLC6A3, COMT | ADRA1A 190/4885CYP2D6 105/4885CYP2C19 178/4885 |
| US-20240016764-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | SLC6A2, CPT1B, CHAT | ADRA1A 885/4885CYP2D6 218/4885CYP2C19 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.